132
Participants
Start Date
March 13, 2023
Primary Completion Date
September 30, 2025
Study Completion Date
October 31, 2025
Lenrispodun
Lenrispodun 30 mg tablets administered orally, once daily.
Placebo
Matching tablets administered orally, once daily.
NOT_YET_RECRUITING
Clinical Site, Albany
RECRUITING
Clinical Site, Falls Church
RECRUITING
Clinical Site, Henrico
RECRUITING
Clinical Site, Rock Hill
RECRUITING
Clinical Site, Decatur
RECRUITING
Clinical Site, Augusta
RECRUITING
Clinical Site, Port Orange
RECRUITING
Clinical Site, Altamonte Springs
NOT_YET_RECRUITING
Clinical Site, Maitland
RECRUITING
Clinical Site, Orlando
RECRUITING
Clinical Site, Orlando
RECRUITING
Clinical Site, Hallandale
RECRUITING
Clinical Site, Coral Springs
RECRUITING
Clinical Site, Miami
RECRUITING
Clinical Site, Boca Raton
RECRUITING
Clinical Site, Tampa
RECRUITING
Clinical Site, Ocala
RECRUITING
Clinical Site, Memphis
RECRUITING
Clinical Site, Farmington Hills
RECRUITING
Clinical Site, Milwaukee
RECRUITING
Clinical Site, Golden Valley
RECRUITING
Clinical Site, Kansas City
RECRUITING
Clinical Site, Dallas
RECRUITING
Clinical Site, Georgetown
RECRUITING
Clinical Site, Austin
RECRUITING
Clinical Site, Phoenix
RECRUITING
Clinical Site, Scottsdale
RECRUITING
Clinical Site, Loma Linda
RECRUITING
Clinical Site, Irvine
RECRUITING
Clinical Site, Kirkland
RECRUITING
Clinical Site, Spokane
Lead Sponsor
Intra-Cellular Therapies, Inc.
INDUSTRY